从临床病例分析房颤“一站式”术后抗栓个体化给药方案及用药监测  

Clinical Cases Analysis of Individualized Drug Administration and Drug Monitoring of Antithrombotic Therapy after“One-stop”Treatment of Atrial Fibrillation

作　　者：徐蕾[1,2] 杨宇[1] 马婧[1] 李平[1] Xu Lei;Yang Yu;Ma Jing;Li Ping(Department of Pharmacy,Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China;Department of Pharmacy,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine)

机构地区：[1]上海交通大学医学院附属新华医院药学部,上海200092 [2]上海交通大学医学院附属瑞金医院药剂科

出　　处：《药物流行病学杂志》2021年第6期404-407,共4页Chinese Journal of Pharmacoepidemiology

基　　金：上海市自然基金面上项目(编号:18ZR1424900);上海交通大学医学院新型冠状病毒感染肺炎抗疫相关药事管理与合理用药研究专项课题(编号:JDYX2020KYZX008)。

摘　　要：房颤"一站式"手术作为一项新兴技术,其术后装置相关性血栓发生率达3.7%~7.2%,然而目前国内相关的抗栓治疗指南缺乏,抗栓策略无统一标准。本文报道1例房颤"一站式"术后老年患者使用新型口服抗凝药达比加群酯抗栓治疗过程,期间药师采用LC-MS/MS法对患者进行达比加群稳态谷浓度监测,合理并及时调整给药剂量,在保障抗栓有效性的同时,也努力规避了出血风险,个体化治疗方案得到了临床的认可和采纳,治疗结果亦令人满意。As a new technology,"one-stop"surgery for atrial fibrillation has an incidence of 3.7%-7.2%postoperative device-related thrombosis.However,currently there is a lack of relevant antithrombotic treatment guidelines in China,and there is no unified standard of antithrombotic strategy.Through analysis of antithrombotic therapy of a"one-stop"postoperative elderly patient with atrial fibrillation who used dabigatran etexilate,the pharmacist did drug monitoring by LC-MS/MS and adjusted the dose immediately.While ensuring the effectiveness of antithrombotic therapy,the pharmacist also strived to avoid the risk of bleeding.The individualized treatment scheme has been recognized and adopted clinically,and the treatment results are satisfactory.

关 键 词：房颤 左心耳封堵术 达比加群酯 血药浓度监测 个体化给药 药学监护 

分 类 号：R97[医药卫生—药品]